ATE552270T1 - Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren - Google Patents

Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren

Info

Publication number
ATE552270T1
ATE552270T1 AT00929704T AT00929704T ATE552270T1 AT E552270 T1 ATE552270 T1 AT E552270T1 AT 00929704 T AT00929704 T AT 00929704T AT 00929704 T AT00929704 T AT 00929704T AT E552270 T1 ATE552270 T1 AT E552270T1
Authority
AT
Austria
Prior art keywords
interaction
inducible factor
hypoxia inducible
test methods
tumor suppressor
Prior art date
Application number
AT00929704T
Other languages
English (en)
Inventor
Peter Ratcliffe
Patrick Maxwell
Christopher Pugh
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE552270T1 publication Critical patent/ATE552270T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00929704T 1999-05-12 2000-05-12 Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren ATE552270T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9911047.0A GB9911047D0 (en) 1999-05-12 1999-05-12 Assay method and means
PCT/GB2000/001826 WO2000069908A1 (en) 1999-05-12 2000-05-12 Interaction between the vhl tumour suppressor and hypoxia inducible factor, and assay methods relating thereto

Publications (1)

Publication Number Publication Date
ATE552270T1 true ATE552270T1 (de) 2012-04-15

Family

ID=10853339

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00929704T ATE552270T1 (de) 1999-05-12 2000-05-12 Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren

Country Status (6)

Country Link
US (3) US6787326B1 (de)
EP (1) EP1179018B1 (de)
JP (3) JP4548944B2 (de)
AT (1) ATE552270T1 (de)
GB (1) GB9911047D0 (de)
WO (1) WO2000069908A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4540294B2 (ja) 2000-09-27 2010-09-08 東亞合成株式会社 ガン細胞または胚性幹細胞にｖｈｌ遺伝子を導入し、発現して得られる宿主細胞
US7105656B2 (en) 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US7919274B2 (en) * 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
WO2002074981A2 (en) 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
US7700754B1 (en) 2001-06-05 2010-04-20 Masahiro Hiraoka Polypeptide for unstabilizing protein in cells under aerobic conditions and DNA encoding the same
US7358043B2 (en) 2001-10-16 2008-04-15 Duke University Proteomic interaction and genomic action determinations in the presence of associated redox state conditions
CN102526045A (zh) * 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US7053046B2 (en) * 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
WO2003074560A2 (en) * 2002-03-05 2003-09-12 Angiogenetics Sweden Ab Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
DE602006016577D1 (de) * 2005-03-11 2010-10-14 Nano Factory Co Ltd Tiermodell mit in echtzeit beobachtbarem krankheitszustand, genkonstrukt zur herstellung davon und verwendung davon
US7214767B2 (en) 2005-05-25 2007-05-08 Hiroshi Kanno VHL peptide
ATE470439T1 (de) 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
KR100859506B1 (ko) * 2005-07-22 2008-09-22 한국과학기술연구원 프롤린 수산화반응에 의한 ｈｉｆ―1 펩타이드와 ｖｂｃ단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
KR20080097446A (ko) 2006-02-16 2008-11-05 피브로겐, 인크. 뇌졸중의 치료를 위한 화합물과 방법
ES2393326T3 (es) * 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
EP2111399A2 (de) * 2006-12-18 2009-10-28 Amgen Inc. Naphthalenon-verbindungen mit prolylhydroxylase-hemmungsaktivität sowie zusammensetzungen daraus und anwendungen davon
KR100847694B1 (ko) * 2007-02-09 2008-07-23 한국과학기술연구원 프롤린기가 수산화된 ＨＩＦ－１α와 ＶＢＣ 단백질 결합을억제하는 저해제 펩타이드 및 그 제조 방법
EP2142509B1 (de) * 2007-04-18 2013-12-04 Amgen, Inc Chinolone und azachinolone, die prolylhydroxylase inhibieren
ES2446418T3 (es) * 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
US8030346B2 (en) * 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
WO2008137084A2 (en) * 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US20100215697A1 (en) * 2009-02-26 2010-08-26 Stanimir Vuk-Pavlovic Methods and materials for making and using vaccines
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
EP2975155A1 (de) * 2014-07-15 2016-01-20 Essilor International (Compagnie Generale D'optique) Verfahren zur physikalischen Dampfabscheidung einer Materialschicht auf Oberflächen von mehreren Substraten
US10444167B2 (en) 2014-11-24 2019-10-15 Halliburton Energy Services, Inc. Determining the leaching profile of a cutter on a drilling tool
WO2016133472A1 (en) * 2015-02-18 2016-08-25 Koc Universitesi Multi-axis piezoresistive force sensor
CN110241120A (zh) * 2019-06-28 2019-09-17 西安医学院 转录、转录后和翻译后多水平低氧调控基因、应用及其调控方法
KR102491095B1 (ko) * 2021-01-22 2023-01-20 한국생명공학연구원 Cas 단백질 및 HIF의 TAD 도메인을 포함하는 단백질 융합체 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803891D0 (sv) * 1998-11-13 1998-11-13 Pharmacia & Upjohn Ab Protein Variants

Also Published As

Publication number Publication date
EP1179018B1 (de) 2012-04-04
JP2010246542A (ja) 2010-11-04
US7709600B2 (en) 2010-05-04
EP1179018A1 (de) 2002-02-13
US6787326B1 (en) 2004-09-07
WO2000069908A1 (en) 2000-11-23
US20100330668A1 (en) 2010-12-30
JP4540728B2 (ja) 2010-09-08
JP4548944B2 (ja) 2010-09-22
GB9911047D0 (en) 1999-07-14
US20050003452A1 (en) 2005-01-06
JP2009022287A (ja) 2009-02-05
JP2003500340A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
GB9911047D0 (en) Assay method and means
EA202192738A1 (ru) Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
WO2019157366A8 (en) Antibody variable domains targeting the nkg2d receptor
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
DE69939864D1 (de) Ppar-gamma modulatoren
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
NO986100L (no) Androgene reseptormodulerende forbindelser og fremgangsmÕter
DE60237917D1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
MXPA01003344A (es) Composiciones y metodos para inmunoterapia especifica de wt1.
CY1108960T1 (el) Αντισωματα αποκλεισμου cripto και οι χρησεις τους
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
BR0211199A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
WO2003079020A3 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
ATE333465T1 (de) Methoden und mittel zur hemmung der cdk4- aktivität
NO993943L (no) Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer
MX2023006773A (es) Composiciones de agentes de union a antigenos de guanilato ciclasa c (gcc) y metodos de uso de estos.
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
NO20010389L (no) Modulering av multippel linje kinase proteiner
NO982588D0 (no) FremgangsmÕte for diagnose og behandling av plate epizelkarsinom
EP4434541A3 (de) Für die delta-1-kette des t-zell-rezeptors spezifische antikörper
AU2002248180A1 (en) Non-apoptotic forms of cell death and methods of modulation